Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer.

ABSTRACT: Peritoneal tumor dissemination and subsequent malignant tumor ascites (MTA) occur unexpectedly and repeatedly in patients with gastrointestinal (GI) cancers, and worsen quality of life and prognosis of the patients. Various treatments have been clinically developed for these patients, while most of the MTA cases are refractory to the treatments. Thus, effective treatments are urgently needed to improve the clinical outcomes. In this study, we identified α-synuclein (SNCA) as an immunological determinant of MTA progression in GI cancer through translational research using mouse tumor models and clinical specimens collected from gastric cancer patients. We found that the SNCA⁺ subsets were significantly increased in CD3⁺ T cells, CD56⁺ NK cells, and CD11b

SUBMITTER: Kudo-Saito C 

PROVIDER: S-EPMC11345905 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature